| 产品描述: | BGT226 (NVP-BGT226 maleate) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells |
| 靶点: |
PI3Kα:4 nM (IC50);PI3Kβ:63 nM (IC50);PI3Kγ:38 nM (IC50);mTOR;Autophagy;PI3K;mTOR;Autophagy |
| 体内研究: |
BGT226 (2.5 and 5 mg/kg; oral administration for 21 days in male athymic mice) causes 34.7% and 76.1% reduction of the tumor growth on day 21 compared with control |
| 参考文献: |
1. Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012 Sep;23(9):2399-408. 2. Chang KY, et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011 Nov 15;17(22):7116-26. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.537 ml |
7.685 ml |
15.37 ml |
| 5 mM |
0.307 ml |
1.537 ml |
3.074 ml |
| 10 mM |
0.154 ml |
0.769 ml |
1.537 ml |
| 50 mM |
0.031 ml |
0.154 ml |
0.307 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |